Stem-Cell Transplantation
Recipient CMV status should determine T-cell depletion
Published in Blood Weekly, April 22nd, 2004
In a recent study, scientists in England "compared the incidence and outcome of preemptively treated cytomegalovirus (CMV) infection, lymphocyte recovery and non-CMV infections between two different TCD modalities, one employing CD34+ selection and T-cell add-back (TCAB), preceded by Campath-1H in vivo (CD34+/TCAB group, n=29), and the other using grafts incubated with Campath-1H in vitro (Campath-1H in vitro group, n=32)."
"The probabilities of CMV reactivation and recurrence were 67% and 83.6% in the CD34+/TCAB group and 42.9%...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2004-04-22)
More Articles from Blood Weekly
- Leukemia Therapy
Specific T-cell replete haploidentical SCT feasible for pediatric ALL - Chronic Myelogenous Leukemia Therapy
Cytogenetic CE alone does not reduce post-SCT imatinib efficacy - Paroxysmal Nocturnal Hemoglobinuria
Membranous glomerulopathy reported after allo-SCT in PNH patient - Stem-Cell Transplantation
Fatal post-SCT androgen-related hepatic adenoma described - Stem-Cell Transplantation
Reservation of PBSCs for DLI at harvest improves postrelapse treatment efficacy - Anemia
Anemia among cancer patients can be treated with human erythropoietin - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
